Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$40.15
-0.5%
$51.49
$39.79
▼
$63.45
$3.92B1.921.68 million shs4.11 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-0.54%-11.07%-18.48%-32.87%-27.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$40.15
-0.5%
$51.49
$39.79
▼
$63.45
$3.92B1.921.68 million shs4.11 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-0.54%-11.07%-18.48%-32.87%-27.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.65
Moderate Buy$72.9381.64% Upside

Current Analyst Ratings Breakdown

Latest CRSP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/10/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingOverweight$110.00
11/4/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Lower Price TargetEqual Weight$75.00 ➝ $70.00
11/4/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Boost Price TargetBuy$88.00 ➝ $90.00
11/3/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingMarket Outperform
11/3/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingBuy$82.00
10/15/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingSell (D-)
10/15/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Initiated CoverageBuy ➝ Neutral$52.00
10/9/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingBuy
10/9/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingBuy
9/28/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingMarket Outperform
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$3.51M1,109.56N/AN/A$16.99 per share2.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$4.74N/AN/AN/A-1,812.07%-25.59%-17.89%N/A

Latest CRSP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/2/2026Q3 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.06-$1.15-$0.09-$1.15$14.75 million$12.67 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.36
16.21
16.21

Institutional Ownership

CompanyInstitutional Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%

Insider Ownership

CompanyInsider Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
39397.00 million91.96 millionOptionable

Recent News About These Companies

Big-name investors pour $100M into DNA therapeutics developer Seawolf
Crispr Therapeutics: More Patients, Same Losses
CRISPR Therapeutics AG $CRSP Shares Sold by GSK plc

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$40.15 -0.22 (-0.54%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$40.33 +0.18 (+0.45%)
As of 07:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.